Annual report

Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥921.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥613.8bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥628.9bn2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥140.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥117.3bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥140.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥97.1bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥106.5bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥77.3bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥85.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥1.83Tat 2024-03-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.35Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.24Tat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥504.3bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.33Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.33Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥856.7bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥754.8bnat 2020-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥204.9bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥166.9bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥146.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥121.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥117.5bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥81.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥85.3bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥84.7bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥62.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥7.4bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥14.0bn2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥71.52023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥59.52022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥58.722021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥51.162020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥56.982019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.472023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥59.482022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.692021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥51.052020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥56.312019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥893.8at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥746.07at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥669.23at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥566.57at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥501.68at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio72.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio63.4%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio60.8%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE8.7%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE9.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE11.7%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees30,591at 2024-03-31Cons.Number of employees
Employees30,207at 2023-03-31Cons.Number of employees
Employees28,294at 2022-03-31dCons.Number of employees
Employees26,482at 2021-03-31dCons.Number of employees
Employees26,438at 2020-03-31dCons.Number of employees
Revenue¥399.8bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥375.0bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥341.4bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥316.4bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥319.0bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥77.0bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥67.8bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥110.7bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥91.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥79.4bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥65.3bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥80.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥112.0bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥99.7bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥87.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥79.0bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥62.8bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥52.0bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥65.3bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥1.44Tat 2024-03-31StandaloneAssets
Total assets¥1.33Tat 2023-03-31StandaloneAssets
Total assets¥1.28Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.26Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.15Tat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥623.6bnat 2024-03-31StandaloneLiabilities
Total liabilities¥566.1bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥813.8bnat 2024-03-31StandaloneNet assets
Net assets / equity¥765.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥765.4bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥725.2bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥687.2bnat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥93.8bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥91.5bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥59.052023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥52.612022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.522021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥34.442020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥43.652019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥59.032023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.592022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥41.492021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥34.372020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥43.122019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥442023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥292020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥282019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥547.68at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥513.67at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥505.54at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥479.13at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥456.22at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio56.6%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE11.1%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE7.4%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.0%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued745,348,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued747,682,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,554at 2024-03-31StandaloneNumber of employees
Employees5,457at 2023-03-31StandaloneNumber of employees
Employees5,377at 2022-03-31dStandaloneNumber of employees
Employees5,247at 2021-03-31dStandaloneNumber of employees
Employees5,087at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-04-01 → 2024-03-31¥4.0bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2024-03-31¥248m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥3.2bn
Blood And Cell Technologies Companyreportable segmentcapex2023-04-01 → 2024-03-31¥17.3bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2024-03-316386 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥168.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥16.4bn
Cardiac And Vascular Companyreportable segmentcapex2023-04-01 → 2024-03-31¥41.5bn
Cardiac And Vascular Companyreportable segmentemployeesat 2024-03-3116940 pure
Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥555.7bn
Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥123.8bn
Medical Care Solutions Companyreportable segmentcapex2023-04-01 → 2024-03-31¥15.6bn
Medical Care Solutions Companyreportable segmentemployeesat 2024-03-316038 pure
Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥197.6bn
Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥19.8bn
—segment totalcapex2023-04-01 → 2024-03-31¥74.4bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥921.6bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥160.0bn
Reconciling Itemsreconcilingcapex2022-04-01 → 2023-03-31¥1.5bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2023-03-31¥243m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥142m
Blood And Cell Technologies Companyreportable segmentcapex2022-04-01 → 2023-03-31¥21.5bn
Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥147.6bn
Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥11.2bn
Cardiac And Vascular Companyreportable segmentcapex2022-04-01 → 2023-03-31¥31.9bn
Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥480.6bn
Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥112.2bn
Medical Care Solutions Companyreportable segmentcapex2022-04-01 → 2023-03-31¥20.9bn
Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥191.7bn
Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥14.8bn
—segment totalcapex2022-04-01 → 2023-03-31¥74.3bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥820.0bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥138.2bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2024-03-31260 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2024-03-311893 pure
Medical Care Solutions Companyreportable segmentemployeesat 2024-03-312332 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,828
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)小  山  秀  明
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)渡  辺  雄  一
Cpa3 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)松  尾  洋  孝
Key audit matters consolidated (text)FilingDateInstantText · Plus
Overview kam consolidated (text)FilingDateInstantText · Plus
Short description kam consolidatedFilingDateInstant_Row1Member
Original text (Japanese)血液・細胞テクノロジーカンパニーに係るのれんの減損損失の認識の要否に関する判断の妥当性
Description including reason kam consolidated (text)FilingDateInstant_Row1MemberText · Plus
Reference kam consolidatedFilingDateInstant_Row1Member
Original text (Japanese)連結財務諸表注記12.のれん及び無形資産(3)のれんの減損テスト
Reference2 kam consolidatedFilingDateInstant_Row1Member
Original text (Japanese)連結財務諸表注記3.重要性がある会計方針(10)非金融資産の減損
Auditors response kam consolidated (text)FilingDateInstant_Row1MemberText · Plus
Short description kam consolidatedFilingDateInstant_Row2Member
Original text (Japanese)売上収益の期間帰属の適切性
Description including reason kam consolidated (text)FilingDateInstant_Row2MemberText · Plus
Reference kam consolidatedFilingDateInstant_Row2Member
Original text (Japanese)連結財務諸表注記3.重要性がある会計方針(15)収益
Auditors response kam consolidated (text)FilingDateInstant_Row2MemberText · Plus
Other information consolidated (text)FilingDateInstantText · Plus
Fee related information consolidated (text)FilingDateInstantText · Plus
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)小  山  秀  明
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)渡  辺  雄  一
Cpa3 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)松  尾  洋  孝
Key audit matters non consolidated (text)FilingDateInstantText · Plus
Overview kam non consolidated (text)FilingDateInstantText · Plus
Short description kam non consolidatedFilingDateInstant_Row1Member
Original text (Japanese)売上高の期間帰属の適切性
Description including reason kam non consolidated (text)FilingDateInstant_Row1MemberText · Plus
Reference kam non consolidatedFilingDateInstant_Row1Member
Original text (Japanese)重要な会計方針(4) 収益及び費用の計上基準
Auditors response kam non consolidated (text)FilingDateInstant_Row1MemberText · Plus
Other information non consolidated (text)FilingDateInstantText · Plus
Fee related information non consolidated (text)FilingDateInstantText · Plus
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior4YearDuration628897000000JPY
Revenue IFRS (5-year summary)Prior3YearDuration613842000000JPY
Revenue IFRS (5-year summary)Prior2YearDuration703303000000JPY
Revenue IFRS (5-year summary)Prior1YearDuration820209000000JPY
Revenue IFRS (5-year summary)CurrentYearDuration921863000000JPY
Profit loss before tax IFRS (5-year summary)Prior4YearDuration106466000000JPY
Profit loss before tax IFRS (5-year summary)Prior3YearDuration97060000000JPY
Profit loss before tax IFRS (5-year summary)Prior2YearDuration114501000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration116137000000JPY
Profit loss before tax IFRS (5-year summary)CurrentYearDuration140829000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior4YearDuration85211000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior3YearDuration77268000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior2YearDuration88813000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration89325000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYearDuration106374000000JPY
Comprehensive income IFRS (5-year summary)Prior4YearDuration59246000000JPY
Comprehensive income IFRS (5-year summary)Prior3YearDuration115732000000JPY
Comprehensive income IFRS (5-year summary)Prior2YearDuration178394000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass